These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 7248480)

  • 1. Bioavailability of propranolol and bendrofluazide formulations.
    McAinsh J; Holmes BF; Baber NS; Young J
    Biopharm Drug Dispos; 1981; 2(2):167-75. PubMed ID: 7248480
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The fixed combination of propranolol and bendrofluazide in the treatment of hypertension.
    Jäättelä A
    Ann Clin Res; 1979 Apr; 11(2):80-2. PubMed ID: 378094
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics of bendroflumethiazide alone and in combination with propranolol and hydralazine.
    Schäfer-Korting M; Mutschler E
    Eur J Clin Pharmacol; 1982; 21(4):315-23. PubMed ID: 7056277
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bioavailability of sustained release propranolol formulations.
    McAinsh J; Baber NS; Holmes BF; Young J; Ellis SH
    Biopharm Drug Dispos; 1981; 2(1):39-48. PubMed ID: 7236870
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative pharmacological and pharmacokinetic observations on propranolol (long acting formulation) and bendrofluazide administered separately and concurrently to volunteers.
    Nicholls DP; Harron DW; McAinsh J; Castle WM; Barker NP; Shanks RG
    Br J Clin Pharmacol; 1982 Nov; 14(5):727-32. PubMed ID: 7138752
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The relative bioavailability of a commercial propranolol hydrochloride tablet in man.
    Roscoe R; Cooper J; Wilson TW; Joshi NN; Midha KK
    Biopharm Drug Dispos; 1982; 3(2):105-14. PubMed ID: 7104460
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The treatment of hypertension with propranolol and bendrofluazide.
    Agrawal RL; Alliott RJ; George M; Gomez G; Trafford JA; Jequier PW; Lishman JD; Turner JR; Baber NS; Dawes PM
    J R Coll Gen Pract; 1979 Oct; 29(207):602-6. PubMed ID: 536969
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bioavailability in man of atenolol and chlorthalidone from a combination formulation.
    McAinsh J; Bastain W; Young J; Harry JD
    Biopharm Drug Dispos; 1981; 2(2):147-56. PubMed ID: 7248478
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of hypertension with a fixed ratio combination of long-acting propranolol and bendrofluazide, and influence of age of the subject.
    Herrick AL; Davis JM; Weir RJ
    Br J Clin Pract; 1989 Jun; 43(6):196-200. PubMed ID: 2597598
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative bioavailability of propranolol: twice-daily versus four times-daily administration.
    Dvornik D; Kraml M; Dubuc J; Patterson-Kreuscher S; Milosovich G; Mullane JF
    J Clin Pharmacol; 1981; 21(11):472-6. PubMed ID: 7334139
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bioavailability in man of atenolol and chlorthalidone from a combination formulation.
    McAinsh J; Holmes BH; Fitzsimons TJ; Young J
    Biopharm Drug Dispos; 1986; 7(3):223-31. PubMed ID: 3730522
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of essential hypertension with a combination of propranolol and bendrofluazide.
    Solomon LR; Dawes PM
    J Int Med Res; 1980; 8(1):34-7. PubMed ID: 7358202
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fixed ratio combination of propranolol and bendrofluazide in the treatment of hypertension.
    Pandhi P; Sharma BK; Sharma PL; Wahi PL
    Int J Clin Pharmacol Ther Toxicol; 1985 Feb; 23(2):92-4. PubMed ID: 3886568
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Stability of bendrofluazide in a low-dose extemporaneously prepared capsule.
    Barnes AR; Nash S
    J Clin Pharm Ther; 1994 Apr; 19(2):89-93. PubMed ID: 8071398
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An assessment of Half-Inderal LA and Inderal LA in the treatment of hypertension in elderly subjects.
    Datta SR
    Br J Clin Pract; 1989 Mar; 43(3):102-8. PubMed ID: 2692687
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of beta blockade bendrofluazide, and prazosin in severe hypertension.
    Marshall AJ; Barritt DW; Pocock J; Heaton ST
    Lancet; 1977 Feb; 1(8006):271-4. PubMed ID: 64803
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Pharmacokinetic studies and bioavailability of bendroflumethiazide in combination with spironolactone].
    Vergin H; Nuss U; Strobel K
    Arzneimittelforschung; 1986 Mar; 36(3):490-5. PubMed ID: 3707669
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetic and pharmacodynamic studies with a new controlled-release formulation of propranolol in normal volunteers: a comparison with other commercially available formulations.
    Perucca E; Grimaldi R; Gatti G; Caravaggi M; Crema F; Lecchini S; Frigo GM
    Br J Clin Pharmacol; 1984 Jul; 18(1):37-43. PubMed ID: 6743489
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Disposition of propoxyphene and propranolol in children.
    Wilson JT; Atwood GF; Shand DG
    Clin Pharmacol Ther; 1976 Mar; 19(3):264-70. PubMed ID: 1261164
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Decreased absorption as a possible cause for the lower bioavailability of a sustained-release propranolol.
    Takahashi H; Ogata H; Warabioka R; Kashiwada K; Ohira M; Someya K
    J Pharm Sci; 1990 Mar; 79(3):212-5. PubMed ID: 2338628
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.